Trade

with

Mylan Inc
(NASDAQ: MYL)
AdChoices
51.22
+0.79
+1.57%
After Hours :
51.22
0.00
0.00%

Open

50.78

Previous Close

50.43

Volume (Avg)

3.40M (4.95M)

Day's Range

50.45-51.41

52Wk Range

36.97-57.52

Market Cap.

18.86B

Dividend Rate ( Yield )

-

Beta

1.19

Shares Outstanding

374.05M

P/E Ratio (EPS)

34.48 (1.46)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 6.91B

    • Net Income

    • 623.71M

    • Market Cap.

    • 18.86B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 8.14

    • PEG (Price/Earnings Growth) Ratio

    • 0.99

    • Beta

    • 1.19

    • Forward P/E

    • 12.56

    • Price/Sales

    • 2.85

    • Price/Book Value

    • 5.75

    • Price/Cash flow

    • 16.13

      • EBITDA

      • 1.58B

      • Return on Capital %

      • 4.17

      • Return on Equity %

      • 18.53

      • Return on Assets %

      • 4.17

      • Book Value/Share

      • 8.91

      • Shares Outstanding

      • 374.05M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • 0.06 (6/27/2007)

      • Dividend Declaration Date

      • 6/18/2007

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 63.25

        • Credit Rating

        • BBB-

        • Analysts

        • 6

        • EPS Estimate

        • 3.55

        • Cashflow Estimate

        • 4.31

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 8.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -2.70

          • -26.33

          • Net Income

            Q/Q (last year)

          • -29.50

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • 6.10

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 44.20

            • 64.72

            • Pre-Tax Margin

            • 9.51

            • 13.77

            • Net Profit Margin

            • 8.14

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 42.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 8.90

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • 6.60

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 2.37

              • 0.33

              • Current Ratio

              • 1.72

              • 1.52

              • Quick Ratio

              • 0.75

              • 0.87

              • Interest Coverage

              • 3.11

              • 6.77

              • Leverage Ratio

              • 4.68

              • 1.91

              • Book Value/Share

              • 8.91

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 35.59

                • 65.79

                • P/E Ratio 5-Year High

                • 39.30

                • 237.47

                • P/E Ratio 5-Year Low

                • 10.58

                • 19.71

                • Price/Sales Ratio

                • 2.89

                • 3.69

                • Price/Book Value

                • 5.84

                • 3.46

                • Price/Cash Flow Ratio

                • 16.13

                • 22.12

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 18.53

                    (12.70)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • 4.17

                    (3.50)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • 8.27

                    (7.60)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • 29.01k

                  • 27.79k

                  • Inventory Turnover

                  • 2.32

                  • 1.80

                  • Asset Turnover

                  • 0.51

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  1.14B
                  Operating Margin
                  16.44
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  16.13
                  Ownership

                  Institutional Ownership

                  91.33%

                  Top 10 Institutions

                  30.20%

                  Mutual Fund Ownership

                  39.60%

                  Float

                  98.76%

                  5% / Insider Ownership

                  0.85%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Mid-Cap Index Fund

                  •  

                    6,399,046

                  • 1.18

                  • 1.71

                  • Vanguard Total Stock Mkt Idx

                  •  

                    6,094,591

                  • 0.60

                  • 1.63

                  • iShares Nasdaq Biotechnology

                  •  

                    4,834,814

                  • -0.47

                  • 1.43

                  • Vanguard Health Care Fund

                  •  

                    4,775,700

                  • 0.00

                  • 1.28

                  • Vanguard Five Hundred Index Fund

                  •  

                    3,883,280

                  • 0.32

                  • 1.04

                  • Vanguard Institutional Index Fund

                  •  

                    3,789,152

                  • -0.99

                  • 1.01

                  • SPDR® S&P 500 ETF

                  •  

                    3,700,937

                  • 1.44

                  • 1.10

                  • PowerShares QQQ

                  •  

                    3,136,540

                  • 0.44

                  • 0.93

                  • Goldman Sachs Growth Opportunities Fund

                  •  

                    2,386,184

                  • -0.57

                  • 0.64

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    27,692,860

                  • +2.27%

                  • 7.41

                  • State Street Corp

                  •  

                    15,661,083

                  • -0.38%

                  • 4.19

                  • Paulson & Company Inc

                  •  

                    12,130,700

                  • 0.00%

                  • 3.24

                  • Goldman Sachs Asset Management, L.P.

                  •  

                    11,704,126

                  • +90.43%

                  • 3.13

                  • BlackRock Fund Advisors

                  •  

                    11,131,342

                  • +0.51%

                  • 2.98

                  • Wellington Management Company, LLP

                  •  

                    10,440,382

                  • -19.19%

                  • 2.79

                  • Discovery Capital Management LLC

                  •  

                    7,376,404

                  • +11.91%

                  • 1.97

                  • BMO Asset Management Inc.

                  •  

                    6,110,910

                  • +3.02%

                  • 1.63

                  • Government Pension Fund of Norway - Global

                  •  

                    5,482,627

                  • -23.42%

                  • 1.28

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Aggressive Growth

                  Style

                  Large Growth

                  Mylan Inc was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharm...moreaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceutical...mores, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted primarily in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company’s competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.lessless

                  Key People

                  Heather Bresch

                  CEO/Director

                  Robert J. Coury

                  Chairman of the Board/Director

                  Rodney L. Piatt

                  Director/Vice Chairman of the Board

                  John D. Sheehan

                  CFO/Executive VP

                  C. B. Todd

                  Director Emeritus

                  • Mylan Inc

                  • 1000 Mylan Boulevard

                  • Canonsburg, PA 15317

                  • USA.Map

                  • Phone: +1 724 514-1800

                  • Fax: -

                  • mylan.com

                  Incorporated

                  1970

                  Employees

                  20,000

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: